跳至主要内容
临床试验/NCT00708851
NCT00708851已完成不适用

A Clinical Evaluation of Safety & Efficacy of Adding an At-home Topical LCD Solution Regimen to Standard Narrowband UVB Phototherapy Administered 3 Times Weekly to Adults With Generalized Plaque Psoriasis.

NeoStrata Company, Inc.2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2007年4月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
12
试验地点
2
主要终点
The Difference in Bilateral Static Physician's Global Assessment (sPGA) Scores, and Erythema, Scaling, and Induration (ESI) Scores of Bilateral Target Lesion Scores Across Visits for Each Condition and Between Conditions.

研究概览

简要总结

The purpose of this study is to determine if combining a daily at-home regimen using an LCD Solution with a 3 times weekly outpatient narrowband UVB phototherapy regimen could be a safe, effective, rapid, and, convenient treatment for plaque psoriasis.

详细描述

Use of coal tar with narrowband (NB) ultraviolet B (UVB) light (the Goeckermen regimen) is an effective treatment for plaque psoriasis that has become impractical in outpatient care mainly due to the inconvenience and aesthetic concerns of coal tar. This study aims to evaluate the safety, efficacy, and convenience of adding a novel liquor carbonis distillate (LCD) (coal tar) solution to standard NB_UVB phototherapy in adults with chronic plaque psoriasis. Patients will apply LCD solution to half the body, twice daily at home and receive outpatient full-body NB-UVB light therapy 3 times a week for up to 12 weeks. A blinded investigator will grade psoriasis severity of body halves and bilateral target lesions and monitor adverse reactions. Patients will rate their psoriasis symptoms and LCD solution aesthetics. Incorporating an at-home regimen with a novel LCD solution into outpatient NB-UVB light therapy is safe, convenient, and effective and can improve psoriasis more quickly than NB-UVB light therapy alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years old or older
  • able and willing to provide written informed consent
  • symmetrical plaque psoriasis
  • able and willing to attend phototherapy sessions and apply LCD at home
  • negative pregnancy test for women of child-bearing potential

排除标准

  • current or recent other treatments for psoriasis
  • hypersensitivity to LCD or UVB light
  • current or previous skin cancer
  • pregnant or nursing mother
  • participating in another clinical trial

研究组 & 干预措施

NB-UVB Light Device (311-315 nm)

Active Comparator

the subject will receive full body NB-UVB light therapy

干预措施: NB-UVB Light Device (311-315 nm) (Device)

LCD Solution with NB-UVB Phototherapy

Experimental

on half of the body will receive LCD while the full body receives NB-UVB therapy

干预措施: LCD Solution with NB-UVB Phototherapy (Other)

LCD Solution with NB-UVB Phototherapy

Experimental

on half of the body will receive LCD while the full body receives NB-UVB therapy

干预措施: NB-UVB Light Device (311-315 nm) (Device)

结局指标

主要结局

The Difference in Bilateral Static Physician's Global Assessment (sPGA) Scores, and Erythema, Scaling, and Induration (ESI) Scores of Bilateral Target Lesion Scores Across Visits for Each Condition and Between Conditions.

时间窗: 12 weeks of treatment

Twelve (12) participants were followed over a 12-week treatment period. Treatment was administered bilaterally as they applied LCD solution to one half of their body while receiving full-body NB-UVB light therapy. The difference in their sPGA, and ESI scores of bilateral target lesions were measured across all visits. PGA scores are calculated using a 6-point scale from 0 (clear) to 5 (very severe). Erythema, induration and scaling scores use a 5-point scale from 0 (none) to 4 (very severe).

次要结局

  • The Difference in Number and Severity of Treatment-related Adverse Reactions Between Conditions.(12 weeks of treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验